Cancer Epigenetics and Nanomedicine

Dr. Prashant Kesharwani is assistant professor of Pharmaceutics at Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya University, Sagar, Madhya Pradesh, India. He has more than 12 years of teaching, research, and industrial experience across various countries. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 350 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, and “SERB-Ramanujan Fellowship Award”. He has presented many invited talks and oral presentations at prestigious scientific peer-conferences, received international acclaims and awards for research contribution, supervised students/junior researchers and actively participated in outreach and scientific dissemination for the service of the wider community. Dr. Chitra Thakur is an Assistant Professor-Research in the Department of Pathology at the Stony Brook Cancer Center, New York, USA. She is a cancer biologist and has expertise in molecular oncology, mouse models of human cancers, analyzing big data in translational research, toxicology, and epigenetics in human cancers. She is the recipient of several internationally acclaimed awards such as the “DFG German Excellence Initiative Award,”, “NIH-Big Data Training for Translational Omics Research” and “American Cancer Society IRG”. With more than 45 research articles published in mainstream scientific journals, she has contributed significantly towards the understanding of the molecular mechanisms in human cancers. She is engrossed in cancer research, teaching, and community outreach initiatives, hence fostering the scientific community and health care professionals engaged in cancer diagnosis, and treatment.

• SECTION 1 Overview of cancer, internal and external factors associated with cancer1. Overview of cancer: Mechanisms of carcinogenesis2. Tumor metabolism and micronutrients: New insights to target malignant tumors3. The role of one-carbon amino acids in tumor-immune metabolism: From oncogenesis to therapy4. Environmental causes of cancer5. Cancer stem cells—Challenges for cancer therapies6. Carving a therapeutic niche for metastatic cancer: Opportunities and challengesSECTION 2 Epigenetics and its importance in cancer therapies7. An overview of epigenetics and cancer8. Metabolic adaptation and epigenetic modulations: Unraveling tumor plasticity under variable tumor microenvironment9. Involvement of epigenetic modifications in cancer stem cells and chemoresistance10. Cancer biomarkers: Where genetics meets epigenetics11. Epigenetics approach in cancer treatment with focus on lung and breast cancer12. Dietary components as epigenetic modifiers and their roles in cancer preventionSECTION 3 Nanomedicine targeting epigenetic machinery in cancer therapy13. Harnessing plant-derived biosynthetic nanomaterials for epigenetic modulation in cancer therapy14. Nanotechnology-enhanced immunotherapy for cancer15. Nanoparticles in metastatic cancer treatment16. Amine-terminated dendrimers: A novel method for diagnose, control and treatment of cancer17. Nanomedicine and epigenome: Possible health risks, benefits, and future perspectives18. Smart cancer nanomedicine: Challenges and future opportunities